- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07585136
Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders
The purpose of this study is to investigate mobilization and collection of HSPCs in patients with bone marrow failure syndromes (BMFS) using granulocyte-colony stimulating factor (otherwise known as Filgrastim) with plerixafor to demonstrate safety and feasibility of collecting HSPCs to advance gene therapy.
Primary objective:
- To characterize the safety of Filgrastim plus plerixafor in participants with life threatening blood disorders as determined by the incidence of adverse events (AEs).
Secondary Objectives:
- To measure the mobilization effects of Filgrastim plus plerixafor in the peripheral blood in participants as determined by peak peripheral blood CD34+ counts.
- To characterize the feasibility of HSPC mobilization using Filgrastim plus plerixafor as determined by peripheral blood CD34+ counts.
- To estimate efficacy of Filgrastim plus plerixafor for HSPC mobilization and apheresis collection in participants as determined by the yield of CD34+ cells (CD34+ cells/kg).
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This is a phase I, open-label, single-center study to evaluate the safety of Filgrastim plus plerixafor stem cell mobilization and apheresis in patients with BMFS. This study will include a screening period with labs, physical examination, and bone marrow evaluation at least 6 months prior to mobilization and apheresis, an intervention period that includes mobilization and apheresis of patient HSPCs, and outpatient follow-up within 7-10 days after intervention. Study staff will follow up with the participant via telephone approximately 30 days after mobilization and apheresis. A bone marrow evaluation will be done within 6 months post-intervention.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
- Name: Alexis Leonard, MD
- Telefonnummer: 888-226-4343
- E-Mail: referralinfo@stjude.org
Studienorte
-
-
Tennessee
-
Memphis, Tennessee, Vereinigte Staaten, 38105-2794
- Rekrutierung
- Saint Jude Children's Research Hospital
-
Kontakt:
- Alexis Leonard, MD
- Telefonnummer: 888-226-4343
- E-Mail: referralinfo@stjude.org
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Participants with a bone marrow failure syndrome with an identified genetic cause willing to donate autologous HSPCs for advancing gene therapy
-
Age ≥ 18 years - 25 years
-
The following hematological parameters need to be met (regardless of transfusion or growth factor support)
- Hb > 8 g/dL
- ANC > 500/mm3
- Platelet > 30,000/mm3
-
Bone marrow evaluation within the preceding 6 months prior to mobilization and apheresis
-
Participants should either have a central venous catheter (CVC) in place, be able to undergo apheresis without requiring a CVC, or agree to having a temporary apheresis catheter placed
-
Karnofsky score >80
-
Negative serologic tests for syphilis, hepatitis B and C, HIV, and HTLV-1/II
-
Female participants of childbearing age should have a negative serum pregnancy test within one week of beginning Filgrastim and plerixafor administration
Exclusion Criteria:
- Participant with sickle cell disease
- Participant who has had a prior autologous or allogeneic HSCT
- Active viral, bacterial, fungal, or parasitic infection
- Total bilirubin >2.5x ULN or transaminases >5x ULN
- Moderate or severe renal failure defined as serum/plasma creatinine >1.5 mg/dL and an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 based on the CKD-Epi equation or the St. Jude equation
- Diagnosis of MDS or other hematologic malignancy
- History of malignancy
- Known allergy to or contraindication for Filgrastim or plerixafor administration, or medications routinely administered during apheresis
- Splenomegaly (size greater than upper limit of normal on examination)
- Any disease or concomitant process that is not compatible with the study as per investigator opinion
- Concomitant treatment with alternative investigational agent or participation in another clinical trial with an investigational drug within 5 half-lives of the investigational agent
- Unwillingness to use a highly effective method of contraception for 1 month after plerixafor or GCSF
- Pregnancy
- Inability or unwillingness of research participant to give written informed consent.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: BDSTEM Treatment
Participants in this study will receive a twice daily dose of Filgrastim (GCSF) (5 mcg/kg BID) SQ starting on day 1 for 5 days followed by a single dose of SQ plerixafor (0.24 mg/kg) on day 5 followed by collection of CD34+ HSPCs via apheresis. A portion of cells collected from the participant will be stored as backup to be used toward future gene therapy endeavors. The remaining cells will be donated for research studies |
Administered twice daily dose starting on day 1 for 5 days. Administered on day 5 via IV. Peripheral venous access or through a central venous catheter approximately 4-5 hours after the dose of plerixafor is given. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of treatment-emergent adverse events following filgrastim plus plerixafor administration
Zeitfenster: From initiation of drug administration through Day +7 to +10 follow-up
|
Safety will be assessed by the incidence, type, and severity of adverse events occurring after administration of filgrastim plus plerixafor in participants with bone marrow failure syndromes. |
From initiation of drug administration through Day +7 to +10 follow-up
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of participants achieving peripheral blood CD34+ counts ≥5 cells/µL
Zeitfenster: From initiation of plerixafor administration through completion of apheresis, or 6 hours after drug administration if apheresis is not performed
|
Feasibility of hematopoietic stem and progenitor cell mobilization will be assessed by peripheral blood CD34+ cell counts measured after plerixafor administration and prior to or during apheresis. |
From initiation of plerixafor administration through completion of apheresis, or 6 hours after drug administration if apheresis is not performed
|
|
Peripheral blood CD34+ kinetics following filgrastim plus plerixafor administration
Zeitfenster: After plerixafor administration through completion of apheresis, or 6 hours after drug administration if apheresis is not performed
|
Peripheral blood CD34+ cell counts will be measured after plerixafor administration and prior to or during apheresis. |
After plerixafor administration through completion of apheresis, or 6 hours after drug administration if apheresis is not performed
|
|
Observed CD34+ cell yield after 1 blood volume apheresis
Zeitfenster: At completion of 1 blood volume apheresis on Day 5
|
CD34+ cell yield (CD34+ cells/kg) collected after processing 1 blood volume during apheresis following filgrastim plus plerixafor administration. |
At completion of 1 blood volume apheresis on Day 5
|
|
Estimated total CD34+ cell yield from projected full-volume apheresis
Zeitfenster: At completion of 1 blood volume apheresis on Day 5
|
Estimated total CD34+ cell yield (CD34+ cells/kg) projected from the observed yield after processing 1 blood volume during apheresis. |
At completion of 1 blood volume apheresis on Day 5
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Alexis Leonard, MD, St. Jude Children's Research Hospital
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Hämatologische Erkrankungen
- Erkrankungen des Knochenmarks
- Hämische und lymphatische Krankheiten
- Störungen des Knochenmarkversagens
- Peptide
- Aminosäuren, Peptide und Proteine
- Proteine
- Untersuchungstechniken
- Therapeutika
- Klinische Labortechniken
- Zytologische Techniken
- Biologische Faktoren
- Kohlenhydrate
- Interzelluläre Signalpeptide und Proteine
- Glykoproteine
- Glykoconjugate
- Biologische Therapie
- Zytapherese
- Entfernung von Blutkomponenten
- Verfahren zur Reduzierung von Leukozyten
- Zelltrennung
- Koloniestimulierende Faktoren
- Hämatopoetische Zellwachstumsfaktoren
- Zytokine
- Granulozyten-Kolonie-stimulierender Faktor
- Leukaphherese
- Filgrastim
- PLERIXAFOR
Andere Studien-ID-Nummern
- BDSTEM
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Individual participant de-identified datasets containing the variables analyzed in the published article will be made available (related to the study primary or secondary objectives contained in the publication). Supporting documents such as the protocol, statistical analyses plan, and informed consent are available through the CTG website for the specific study. Data used to generate the published article will be made available at the time of article publication. Investigators who seek access to individual level de-identified data will contact the computing team in the Department of Biostatistics (ClinTrialDataRequest@stjude.org) who will respond to the data request.
IPD-Sharing-Zeitrahmen
Data will be made available at the time of article publication.
IPD-Sharing-Zugriffskriterien
Data will be provided to researchers following a formal request with the following information: full name of requestor, affiliation, data set requested, and timing of when data is needed. As an informational point, the lead statistician and study principal investigator will be informed that primary results datasets have been requested.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .